Day: 13 April 2017

The U.S. Food and Drug Administration approves first biologic for treatment of eczema

On March 28th 2017, the U.S. Food and Drug Administration (FDA) approved a new drug called dupilumab (brand name: Dupixent) for the treatment of adults with moderate-to-severe atopic dermatitis (also known as atopic eczema) that is not adequately controlled with topical treatment, or for whom topical treatments are not appropriate. This new drug is administered […]